Chemotherapy plus endocrine therapy increases long-term recurrence-free survival in women with high-risk HR+ breast cancer
Results from TAILORx trial presented at ESMO 2019
Are we reaching a turning point in metastatic prostate cancer?
PROfound study shows benefit in radiological progression-free survival with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant prostate cancer
Targeting HER2 amplifications in metastatic colorectal cancer: searching for the most active combination therapy?
Mixed results from the the HERACLES-B, TRIUMPH and MOUNTAINEER trials
Closing the clinician–patient gap with patient-reported outcomes
PROs encourage patient-centred cancer care
‘Living’ anticancer medicines: has a new era started?
The benefits of adoptive T-cell therapy—where T-cells are given to induce a specific immune response—are moving closer to reality for patients with solid tumours
Two CDK 4/6 inhibitors prolong survival in HR+/HER2- breast cancer in pre- and post-menopausal women
Results from the MONARCH 2 and MONALEESA-3 trials
Immunotherapy fails to improve PFS and OS in relapsed mesothelioma
Results from the PROMISE-meso trial presented